EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis

Alexandre Louvet, Julien Labreuche, Thong Dao, Thierry Thévenot, Frédéric Oberti, Christophe Bureau, Thierry Paupard, Eric Nguyen-Khac, Anne Minello, Brigitte Bernard-Chabert, Rodolphe Anty, Faustine Wartel und 8 weitere

JAMA · 09.05.2023 · 329 (18) · 1558

DOI: 10.1001/jama.2023.4902 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, erschienen am 09.05.2023. Verfasst von Alexandre Louvet und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Lille, CHU de Lille, Service des maladies de l'appareil digestif, Hôpital Huriez, INFINITE-U1286, Lille, France. Hauptthemen laut MEDLINE: Amoxicillin-Potassium Clavulanate Combination, Anti-Bacterial Agents, Antibiotic Prophylaxis, Hepatitis, Alcoholic. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The benefits of prophylactic antibiotics for hospitalized patients with severe alcohol-related hepatitis are unclear.

Objective

To determine the efficacy of amoxicillin-clavulanate, compared with placebo, on mortality in patients hospitalized with severe alcohol-related hepatitis and treated with prednisolone. Design, Setting, and Participants Multicenter, randomized, double-blind clinical trial among patients with biopsy-proven severe alcohol-related hepatitis (Maddrey function score ≥32 and Model for End-stage Liver Disease [MELD] score ≥21) from June 13, 2015, to May 24, 2019, in 25 centers in France and Belgium. All patients were followed up for 180 days. Final follow-up occurred on November 19, 2019.

Intervention

Patients were randomly assigned (1:1 allocation) to receive prednisolone combined with amoxicillin-clavulanate (n = 145) or prednisolone combined with placebo (n = 147). Main Outcome and Measures The primary outcome was all-cause mortality at 60 days. Secondary outcomes were all-cause mortality at 90 and 180 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants with a MELD score less than 17 at 60 days; and proportion of patients with a Lille score less than 0.45 at 7 days.

Results

Among 292 randomized patients (mean age, 52.8 [SD, 9.2] years; 80 [27.4%] women) 284 (97%) were analyzed. There was no significant difference in 60-day mortality between participants randomized to amoxicillin-clavulanate and those randomized to placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [ P = .33]; between-group difference, −4.7% [95% CI, −14.0% to 4.7%]; hazard ratio, 0.77 [95% CI, 0.45-1.31]). Infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, −11.8% [95% CI, −23.0% to −0.7%]; subhazard ratio, 0.62; [95% CI, 0.41-0.91]; P = .02). There were no significant differences in any of the remaining 3 secondary outcomes. The most common serious adverse events were related to liver failure (25 in the amoxicillin-clavulanate group and 20 in the placebo group), infections (23 in the amoxicillin-clavulanate group and 46 in the placebo group), and gastrointestinal disorders (15 in the amoxicillin-clavulanate group and 21 in the placebo group). Conclusion and Relevance In patients hospitalized with severe alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone did not improve 2-month survival compared with prednisolone alone. These results do not support prophylactic antibiotics to improve survival in patients hospitalized with severe alcohol-related hepatitis. Trial Registration ClinicalTrials.gov Identifier: NCT02281929

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsAntibiotic ProphylaxisHepatitis, AlcoholicFemaleHumansMaleMiddle AgedEnd Stage Liver DiseaseHepatitisPrednisoloneSeverity of Illness IndexHospitalizationAnti-Inflammatory AgentsGlucocorticoidsAdult

Substanzen

Amoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsPrednisoloneAnti-Inflammatory AgentsGlucocorticoids

Autor:innen und Institutionen

  • Université Lille, CHU de Lille, Service des maladies de l'appareil digestif, Hôpital Huriez, INFINITE-U1286, Lille, France.
  • Unité de biostatistiques, CHU de Lille, Lille, France.
  • Service d'hépato-gastroentérologie, CHU de Caen, Caen, France.
  • Service d'hépatologie, Hôpital Jean-Minjoz, CHU de Besançon, Besançon, France.
  • Service d'hépato-gastroentérologie, CHU d'Angers, Angers, France.
  • Service d'hépatologie, CHU de Toulouse, Toulouse, France.

Zitieren

APA

Louvet, A., Labreuche, J., Dao, T., Thévenot, T., Oberti, F., Bureau, C., Paupard, T., Nguyen-Khac, E., Minello, A., Bernard-Chabert, B., Anty, R., Wartel, F., Carbonell, N., Pageaux, G. P., Hilleret, M. N., Moirand, R., Nahon, P., Potey, C., Duhamel, A., & Mathurin, P. (2023). Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis. JAMA, 329(18), 1558. https://doi.org/10.1001/jama.2023.4902

Vancouver

Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, et al. Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis. JAMA. 2023;329(18):1558. doi:10.1001/jama.2023.4902

BibTeX
@article{Louvet2023,
  author = {Louvet, Alexandre and Labreuche, Julien and Dao, Thong and Thévenot, Thierry and Oberti, Frédéric and Bureau, Christophe and Paupard, Thierry and Nguyen-Khac, Eric and Minello, Anne and Bernard-Chabert, Brigitte and Anty, Rodolphe and Wartel, Faustine and Carbonell, Nicolas and Pageaux, Georges-Philippe and Hilleret, Marie-Noelle and Moirand, Romain and Nahon, Pierre and Potey, Camille and Duhamel, Alain and Mathurin, Philippe},
  title = {Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {18},
  pages = {1558},
  doi = {10.1001/jama.2023.4902}
}
Kostenlos starten →